Free Trial
NASDAQ:VCYT

Veracyte (VCYT) Stock Price, News & Analysis

Veracyte logo
$28.61 -0.46 (-1.58%)
Closing price 04:00 PM Eastern
Extended Trading
$28.45 -0.16 (-0.56%)
As of 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Veracyte Stock (NASDAQ:VCYT)

Key Stats

Today's Range
$28.25
$29.06
50-Day Range
$23.03
$31.00
52-Week Range
$22.61
$47.32
Volume
1.04 million shs
Average Volume
1.16 million shs
Market Capitalization
$2.25 billion
P/E Ratio
86.70
Dividend Yield
N/A
Price Target
$40.90
Consensus Rating
Moderate Buy

Company Overview

Veracyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

VCYT MarketRank™: 

Veracyte scored higher than 48% of companies evaluated by MarketBeat, and ranked 600th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Veracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Veracyte has only been the subject of 1 research reports in the past 90 days.

  • Read more about Veracyte's stock forecast and price target.
  • Earnings Growth

    Earnings for Veracyte are expected to grow by 5.88% in the coming year, from $0.68 to $0.72 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Veracyte is 86.70, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.62.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Veracyte is 86.70, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.83.

  • Price to Book Value per Share Ratio

    Veracyte has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Veracyte's valuation and earnings.
  • Short Interest

    There is no current short interest data available for VCYT.
  • Dividend Yield

    Veracyte does not currently pay a dividend.

  • Dividend Growth

    Veracyte does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for VCYT.
  • News Sentiment

    Veracyte has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Veracyte this week, compared to 7 articles on an average week.
  • Search Interest

    Only 7 people have searched for VCYT on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Veracyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VCYT Stock News Headlines

This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
Veracyte: Q2 Earnings Brings My Position Out Of Mothballs
Craig-Hallum Sticks to Its Buy Rating for Veracyte (VCYT)
Craig-Hallum Remains a Buy on Veracyte (VCYT)
See More Headlines

VCYT Stock Analysis - Frequently Asked Questions

Veracyte's stock was trading at $39.60 on January 1st, 2025. Since then, VCYT shares have decreased by 27.8% and is now trading at $28.61.

Veracyte, Inc. (NASDAQ:VCYT) released its quarterly earnings data on Monday, February, 24th. The biotechnology company reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.07. The biotechnology company earned $118.63 million during the quarter, compared to analysts' expectations of $110.73 million. Veracyte had a trailing twelve-month return on equity of 6.07% and a net margin of 5.50%.
Read the conference call transcript
.

The following companies are subsidiaries of Veracyte: HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.

Veracyte's top institutional shareholders include Artisan Partners Limited Partnership (8.04%), ARK Investment Management LLC (4.85%), State Street Corp (4.03%) and Geode Capital Management LLC (2.47%). Insiders that own company stock include Rebecca Chambers, John Leite, Giulia C Kennedy, Bonnie H Anderson, Jonathan Wygant, Jonathan Wygant, Evan/ Fa Jones, John L Bishop, Jens Holstein, Muna Bhanji and Karin Eastham.
View institutional ownership trends
.

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
2/24/2025
Today
8/27/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Healthcare
Current Symbol
NASDAQ:VCYT
CIK
1384101
Employees
790
Year Founded
2006

Price Target and Rating

High Price Target
$50.00
Low Price Target
$28.00
Potential Upside/Downside
+43.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.33
Trailing P/E Ratio
86.70
Forward P/E Ratio
42.07
P/E Growth
N/A
Net Income
$24.14 million
Net Margins
5.50%
Pretax Margin
6.05%
Return on Equity
6.07%
Return on Assets
5.53%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.43
Quick Ratio
5.10

Sales & Book Value

Annual Sales
$445.76 million
Price / Sales
5.05
Cash Flow
$1.00 per share
Price / Cash Flow
28.50
Book Value
$15.52 per share
Price / Book
1.84

Miscellaneous

Outstanding Shares
78,670,000
Free Float
77,571,000
Market Cap
$2.25 billion
Optionable
Optionable
Beta
1.97

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:VCYT) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners